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We don’t choose our parents or our siblings. Still, what they share with us in terms of 
genes and environment will affect us throughout life. So it matters what family we are born 
into, but only to a certain extent. We are still individuals with the possibility to be totally 
unique. 
To my family 
  
 
ABSTRACT 
During the last decades there has been an upsurge of studies investigating how early life 
exposures may affect subsequent health outcomes in childhood. For instance, low birth 
weight and exposure to antibiotics during fetal or early life have been suggested to increase 
the risk of childhood asthma. Twin- and sibling comparisons can help to account for 
confounding factors shared within families and to shed light on potential causal pathways.  
Thus, in Study I, we aimed to investigate if low birth weight, as a proxy for fetal growth 
restriction in twins, was associated with the development of asthma in a cohort of 10 918 
Swedish twins aged 9 or 12 years. We found a significant association which was thought to 
be explained by unique individual factors and not due to familial confounding or gestational 
age. It can be speculated that restricted fetal growth affects lung development in utero which 
influences the risk of developing asthma in childhood. 
In Study II, we aimed to further understand the adverse effects of restricted fetal growth, by 
specifically investigating its association with childhood lung function in a cohort of 576 twins 
aged 9-14 years at invitation to the study. We found a significant association between fetal 
growth restriction and reduced forced expiratory volume in the first second, which could be 
explained by unique factors of each twin. Similar effects were found in non-asthmatic 
individuals, whereas other factors may be of importance for the association between fetal 
growth and lung function in individuals with asthma.  
To be able to study asthma in register-based studies, a valid measure of the disease is needed. 
In Study III, medical records for roughly 1700 individuals, corresponding to prescription 
dates of asthma medications or to discharge dates accompanying asthma diagnoses and 
identified from population-based drug- and patient registers, were collected from health care 
units and evaluated against pre-defined criteria of asthma. We found a high positive 
predictive value for asthma medication as a proxy for asthma in older children and the 
majority of children with an asthma diagnosis in the patient register fulfilled pre-defined 
criteria of asthma.  
In Study IV, the previously suggested association between antibiotic exposure in fetal and 
early life and childhood asthma (based on the validated outcome measure from Study III) was 
investigated in a cohort of 493 785 children. We found an association between antibiotic 
exposure both in fetal and early life and asthma. Yet, sibling control analyses suggested that 
the associations were due to shared factors within families, and confounding by indication or 
reverse causation due to respiratory infections.  
In conclusion, shared genetic and environmental factors contributed to the association 
between antibiotics and asthma, but not between fetal growth and asthma and lung function, 
respectively. Genetically informed designs to control for familial confounding are useful 
tools to help provide a clearer understanding of the etiology of asthma. In addition, asthma 
identified from population-based registers can be used as a validated outcome measure and 
contribute towards future studies on asthma using register-based data.  
  
 
SVENSK SAMMANFATTNING 
Under de senaste decennierna har ett stort fokus lagts på att försöka förstå hur faktorer under 
fosterlivet eller tidiga barnår påverkar individens hälsa senare i livet. Det har exempelvis 
föreslagits att låg födelsevikt, exponering för antibiotika under fostertiden eller att barnet 
själv har blivit behandlat med antibiotika tidigt i livet leder till en ökad risk för astma 
senare i barndomen. Tvilling- och syskonstudier kan bidra till ökad förståelse om 
sambanden är kausala eller om de är orsakade av genetik- och miljöfaktorer som delas inom 
familjer. 
I studie I undersökte vi sambandet mellan låg födelsevikt och astma i barndomen. Studien 
omfattade 10 918 tvillingar, 9 eller 12 år gamla, och våra resultat tyder på att låg 
födelsevikt ökar risken för astma oavsett om barnet föds för tidigt eller i fullgången tid, 
samt oberoende av delade genetik- och miljöfaktorer. Resultaten skulle kunna tolkas som 
att hämmad fostertillväxt påverkar fostrets lungutveckling och därmed risken för astma.  
I studie II studerade vi därför om fostertillväxt påverkar lungfunktionen i barndomen och 
om ett eventuellt samband påverkas av astma. Våra resultat, baserade på 576 tvillingar i 
åldrarna 9-14 år, tyder på att hämmad fostertillväxt leder till försämrad lungfunktion. 
Sambandet kunde inte förklaras av för tidig födelse eller delade genetik- och miljöfaktorer, 
och sågs även hos barn utan astma. Det förefaller dock som att andra faktorer verkar 
påverka sambandet mellan fostertillväxt och lungfunktion hos dem som har astma.  
I Sverige finns det flera nationella hälsoregister. För att kunna studera astma i register-
baserade studier behövs ett bra utfallsmått. I studie III validerade vi således mått på astma i 
journaler för ca 1700 individer från primär- och specialistsjukvården, identifierade från 
hälsoregistren. Våra resultat tyder på att astmaläkemedel rapporterade i 
Läkemedelsregistret kan användas som ett precist mått på astma hos barn, och att 
majoriteten av barn som har fått en astmadiagnos i specialistsjukvården uppfyllde 
förbestämda kriterier för en astmadiagnos.  
I studie IV undersökte vi det tidigare föreslagna sambandet mellan antibiotika under 
fostertiden eller tidigt i livet och astma i barndomen i en syskonstudie, där astma 
identifierats från hälsoregistren (baserat på studie III). Studien omfattande nästan en halv 
miljon barn och våra resultat tyder på att antibiotika i sig inte orsakar astma utan att 
sambandet orsakas av delade faktorer inom familjer samt luftvägsinfektioner.   
Sammanfattningsvis talar våra resultat för att delade genetik- och miljöfaktorer bidrog till 
sambandet mellan antibiotika och astma, men inte till sambandet mellan hämmad 
fostertillväxt och astma respektive lungfunktion. Vi har också visat att astma identifierat från 
hälsoregister kan fungera som ett bra mått på astma, och kan användas i framtida studier. 
Slutligen, tvilling- och syskonstudier i kombination med information från populations-
baserade register kan bidra till ökad förståelse av tidiga orsaker till astma hos barn. 
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1 INTRODUCTION 
1.1 ASTHMA 
“Every breath counts”, the slogan of the European Respiratory Society 
1.1.1 History  
People have suffered from asthma for millennia. The term asthma originates from the Greek 
word aazein which means to pant or exhale with open mouth (1). First descriptions of asthma 
symptoms in writing are found in the Illiad of Homer (700 BC) and were first used as a 
medical term by the schools of Hippocrates (460-357 BC), even though asthma then was 
more looked upon as a symptom related to any type of dyspnea and not as clinical entity in 
itself. Five hundred years later, Aretaeus the Cappadocian, and much later Floyer in his 
Treaties of Asthma (in 1698), described asthma largely matching the clinical descriptions 
used today (2). 
1.1.2 Prevalence 
Asthma is a common chronic disease among children worldwide (3) and approximately one 
in ten children in Sweden has asthma (4, 5) (Figure 1). It is a disease afflicting all 
socioeconomic classes; however, low socioeconomic status has been reported to increase the 
disease risk (6). While mortality and hospitalization rates of asthma have decreased in the  
Figure 1. Prevalence of current wheeze according to a written questionnaire in 13–14 year olds from 
the Phase Three of the International Study of Asthma and Allergies in Childhood. The symbols 
indicate prevalence values of <5% (blue square), 5 to<10% (green circle), 10 to <20% (yellow 
diamond) and >20% (red star).  From Lai CK, et al. Thorax. 2009;64(6):476-83. Reproduced with 
permission from BMJ Publishing Group Ltd.  
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last decades (7, 8) the prevalence of the disease has increased all around the world (9). 
Although some recent studies have suggested that the increase in asthma prevalence seem to 
have reached a plateau (10-12), the direct and indirect costs for asthma are, and will continue 
to be, high (13). 
1.1.3 Characteristics  
Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. 
It is defined by a history of recurrent episodes of wheezing, breathlessness, cough, and 
tightness in the chest, which reverse spontaneously or after use of medication (14, 15). The 
childhood asthma disease spectrum is widely recognized and it has been suggested that 
asthma is not just one disease, but many united by some common clinical features such as 
intermittent wheezing and reversible airway obstruction (15).  
The term ‘phenotype’ can be used to describe any observable properties or traits of an 
organism, and is supposed to arise from the interaction of the individual’s genes with the 
environment. Examples of different phenotypes of asthma are atopic and non-atopic 
asthma, different wheezing phenotypes (transient, intermediate-onset, late-onset and 
persistent), and obese non-eosinophilic asthma (15-19). The disease severity differs from 
child to child, and the disability associated with asthma can differ with the level of 
treatment and disease control (13, 14, 20).  
There are three characteristic pathophysiological changes seen in the asthma patient (14, 15); 
1) the presence of airway inflammation, where more than 100 different mediators 
(chemokines, cytokines, histamine etc.) have been identified; 2) structural changes often 
described as airway remodeling with increased smooth muscles, mucus hyper secretion and 
narrowing of the airways, due to contraction of smooth muscle and local edema, and; 3) 
airway hyper responsiveness, due to stimuli of free nerve ends that are uncovered when the 
epithelial in the airways is damaged.  
1.1.4 Clinical diagnosis  
The majority of Swedish children receive their asthma diagnosis in the primary health care 
clinics or at specialist pediatric outpatient clinics. A diagnosis is based on a thorough 
patient history regarding current symptoms, family history of asthma and allergic disease, 
home environment, potential triggers, and previous medical history, together with a clinical 
examination including measures of lung function and allergy tests.  
Dynamic spirometry and lung function  
Lung function is one important determinant of asthma, and can be evaluated through 
dynamic spirometry from school-age and onwards (21), whereas other techniques may be 
used in younger children (22). Spirometry is a standardized test in terms of performance, 
methodology and equipment specifications (21). The procedure is highly dependent on the 
individual’s cooperation, and imprecision in the lung function measurement may arise when 
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competent guidance and support from trained personnel is lacking. A reversibility test with 
inhalation of a short-acting bronchodilator may identify obstructive airways (21).  
The procedure creates a flow-volume loop, where at the start of the test, both flow and 
volume are equal to zero (Figure 2). When the patient exhales forcibly, the curve rapidly 
mounts to a peak, which is referred to as the peak expiratory flow (PEF). After the PEF, the 
curve descends and the flow decreases as more air is expired. A normal flow-volume loop 
will descend in a fairly straight line from the top until reaching the bottom, where the forced 
vital capacity (FVC) is measured. The forced expiratory volume in the first second (FEV1) is 
the volume of air which can be forcibly exhaled from the lungs during the first second of a 
FVC procedure.  
 
Figure 2. Spirogram with a normal flow-volume loop and a concave flow-volume loop before 
bronchodilator (pre-β2), indicating airflow limitation, and after bronchodilator (post-β2). 
Characteristics of the spirogram in individuals with obstruction of the airways, such as 
individuals with asthma, include a concave flow-volume loop, a lower FEV1 to FVC ratio 
indicating obstruction, and lower levels of FEV1 before bronchodilator use in relation to 
reference values taking age, sex, height and ethnicity into account (Figure 2) (14, 23). A 
clinically relevant threshold is commonly defined as <80% of the predicted FEV1 value or as 
<LLN (lower limits of normal) in z-scores, which is usually <-1.64 standard deviations from 
the average (23). In addition, ≥12% reversibility, assessed as percent change in FEV1 from 
pre to post inhalation of a bronchodilator, is in line with a diagnosis of asthma. However, 
individuals with lower levels of reversibility (~10%) may have some relief from symptoms 
with improved treatment. It should also be noted that lung function measurements can be 
normal in asthmatic individuals with well-controlled asthma (14). In cases when the 
spirometry is normal, but the patient history still suggests asthma, other diagnostic tools 
may be used (14, 24).  
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Volume (L) 
 
 
 
PEF 
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1.1.5 Treatment 
The treatment of asthma is both pharmacological and non-pharmacological (which involves 
environmental interventions such as elimination of allergens or other triggers). 
Pharmacological treatments include inhaled β2-agonists, inhaled corticosteroids (ICS) and 
leukotriene receptor antagonists (LTRA) (Figure 3)(15).  
 
Figure 3. Pharmacological treatment of asthma in children ≥6 years of age, based on treatment 
algorithm recommended by the Swedish Pediatric Society’s section of Allergy. Short-acting β2-
agonists should be used at all levels if the child has symptoms. The arrow indicates the importance of 
increasing treatment when needed or reducing treatment when possible. For exact dosages and 
treatment algorithm in younger children, see www.barnallergisektionen.se or www.fass.se  
1.1.6 Measures of asthma in observational studies 
Owing to the variable nature of asthma symptoms both between and within individuals, 
clinical assessment is regarded the best method to identify asthma (25). However, medical 
examinations are costly and other methods such as child and parental answers to standardized 
questionnaires, e.g. those developed in the International Study of Asthma and Allergies in 
Childhood  (ISAAC) (26), have often been used and proved valid in measuring prevalence of 
asthma symptoms (27, 28).  
Sweden has a long tradition of register-based research (29). Using register-based data is one 
way to make use of already collected longitudinal information for a large number of 
individuals. Using such data limits costs, time spent on collection, and also avoids potential 
recall bias. As the data are population-based, the findings are also generalizable, at least 
within the specific country and time period. As asthma in Sweden is often diagnosed in the 
primary health care clinics, the diagnosis will not be recorded in the patient register as it only 
includes information from in- and outpatient hospital clinics (30). Instead, a validated 
measure, based on filled prescriptions of asthma medication, may function as proxy for the 
disease.   
  
Sporadic and mild 
symptoms 
•Inhaled short-
acting β2-agonist 
when needed 
Recurrent 
symptoms ≥ 3 
times/week 
•ICS in low to 
moderate dose; 
or LTRA (as an 
alternative to ICS 
in low dose) 
Symptoms 
despite ICS 
•Add long-acting 
β2-agonist  
and/or LTRA 
Still persistent 
symptoms 
•ICS in high dose, 
long-acting β2-
agonist  and 
LTRA 
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1.2 EARLY LIFE ORIGINS OF ASTHMA  
Today, we know that asthma is a multifactorial disease where environmental and genetic 
factors interplay (31). Numerous environmental factors have been reported to increase the 
risk of asthma such as viral infections, pre- and postnatal exposure to tobacco smoke, air 
pollution and low socio-economic status. Others have suggested that children growing up on 
farms or have older siblings may have lower risk of asthma. In addition, numerous genetic 
variants have been associated with asthma. While these factors are important, they lie outside 
the scope of this thesis. The focus of this thesis has been to further study fetal growth and 
exposure to antibiotics in fetal and early life as potential risk factors for asthma. No specific 
genetic variants are addressed in this thesis. Instead, genetic factors that are shared within 
twin pairs and siblings in families are taken into account in the analyses as potential familial 
confounders for the associations between fetal growth/antibiotics and asthma/lung function. 
1.2.1 Fetal growth 
“And the day came when the risk to remain tight in a bud was more painful than the risk it 
took to blossom” Anaïs Nin* 
Pregnancy duration and antenatal care in Sweden 
In Sweden, most pregnant women attend an antenatal care clinic from approximately week 
10 of pregnancy up until delivery, with more frequent visits closer to the expected due date. 
Duration of pregnancy can be estimated according to Naegele’s rule resulting in a pregnancy 
duration of approximately 280 days (40 weeks) (32). The fetus’ gestational age, can also be 
estimated by ultrasound, which has been routinely offered to all pregnant women in Sweden 
around week 16-21, since the 1990’s and accepted by almost all women (33). A term birth 
takes place between week 37 and 42 of gestation. Delivery before week 37 is thus defined as 
preterm and after week 42 post-term. The pregnancy duration is furthermore divided into 
three trimesters; 1
st
 (day 1-91), 2
nd
 (day 92-189) and 3
rd
 (day 190 to delivery).  
Birth weight, fetal growth restriction and small for gestational age 
Birth weight is the product of both gestational age and fetal growth. Normal birth weight for a 
term infant in Sweden is between 2700 and 4400 grams (34, 35) and low birth weight is 
defined as a weight below 2500 grams (36). Historically, birth weight has frequently been 
used by many countries as an indicator for fetal growth, since it is a practical and inexpensive 
measurement (36). However, birth weight is a single-point measurement and does not take 
gestational age into account.  
At the antenatal care clinics, rough estimates of fetal growth is measured throughout the 
pregnancy usually based on maternal weight gain, symphysis-fundus height measurements 
and complemented by ultrasound measurements if any deviations from the expected growth 
curve occur (37, 38). ‘Fetal growth restriction’ implies that fetal growth has been restricted by 
                                                 
*
Author disputed; however, the quote is frequently attributed to Anaïs Nin, but without a specific source to her 
work. 
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Abnormal placentation, placenta 
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factors affecting the intrauterine environment or the delivery of nutrients to the fetus, which 
prevents the fetus to reach its full growth potential (37). A surrogate, but not strictly 
synonymous, term that is usually used instead, is ‘small for gestational age’ (SGA) which, by 
definition, implies that the birth weight falls below the 10
th
 percentile (39) or <2 SD below 
the mean weight for sex-specific gestational age (35). However, it should be recognized that 
SGA infants may either be pathologically or constitutionally small.  
The determinants of fetal growth are a fetus with a certain growth potential, a space to grow 
in and supply line to enable it. The mother influences the potential for growth both by 
providing genes and intrauterine environment (which in turn will be a result of both her genes 
and environment). Determinants of fetal growth can be divided into genetic, demographic, 
placental, environmental and medical factors, where the most common causes for restricted 
fetal growth in the western world are placental insufficiency and smoking (Figure 4) (37, 40-
42).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Determinants of fetal growth. Figure modified from Tedner SG et al. Clin Exp Allergy 
2012;42(10):1430-47. Reproduced with permission from John Wiley and Sons.  
Fetal growth and respiratory health 
Appropriate fetal growth is important for health in both the short and the long term 
perspective (37, 43, 44). The first researchers to propose that early life deprivation could 
predispose later health, more specifically the risk of coronary heart disease, in what has 
become known as the ‘fetal origin hypothesis’, were David Barker and Clive Osmond in 
1986 (45, 46), building on findings from others (47-49). The hypothesis has been elaborated 
and refined several times and evolved into the Developmental Origins of Health and Disease 
(DOHaD) hypothesis, and suggests that the fetus makes physiological adaptations in response 
Medical 
Preeclampsia, diabetes, 
hypoxemia, renal disease, 
intrauterine infections, 
congenital malformations 
Demographic 
Maternal age, 
ethnicity, parity,  
body size, socio-
economic status,  
multiple gestations, 
child’s sex 
 
Environmental 
Nutrition, smoking,  
drugs, high altitude 
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to under-nutrition in utero to prepare itself for postnatal conditions. These adaptations may be 
beneficial in utero, but may be unfavorable if the postnatal environment has been wrongly 
‘predicted’(50). There is increasing epidemiological evidence that respiratory health is 
similarly modified through perinatal experiences, as proposed in the Developmental Origins 
of Respiratory Health and Disease (DORHaD) concept (44, 51).  
Overview of lung development 
The development of the lung is initiated around 4 weeks of gestation (embryonic phase), as a 
derivate of the foregut and by the sixth week of gestation, the two lungs can be distinguished 
as separate structures (52). During the next stage (pseudo glandular phase), all conducting 
airways and blood vessels are formed and epithelial cells appear, followed by growth and 
maturation of the peripheral airways, and differentiation of epithelial cells to form type 1 and 
type 2 alveolar cells (canicular phase). Alveoli start to appear in week 29 (saccular-alveolar 
phase) and continuously increase in number throughout the pregnancy. By 40 weeks of 
gestation, approximately 100-150 million alveoli have formed. Although numbers of alveoli 
are thought to be complete by 2–4 years of age, alveoli might have the capability to 
multiply beyond this age (52, 53). After birth, lung size increases proportionally with age, 
height, sex and ethnicity (23). Maximum lung volumes are reached around the age of 22 
years in men and slightly earlier in women, after which point FEV1 and FVC decline with 
age, even in healthy individuals due to gradual loss of elasticity (52).  
Birth characteristics and asthma and lung function 
Previous studies investigating birth characteristics such as birth weight, gestational age and 
fetal growth and asthma and lung function have found conflicting results. In studies linking 
birth weight with asthma some have suggested an increased risk of asthma with low birth 
weight (54-57), or an increased risk with high birth weight (58), while still others have found 
no association (59-62). Furthermore, while some have found an association between 
gestational age and asthma (54, 63, 64), others have not (56, 61, 62). Studies that have 
investigated the association between fetal growth and asthma are more sparse, potentially due 
to difficulties in properly assessing fetal growth. However, studies using SGA as marker of 
fetal growth have also found inconsistent results where some have indicated an increased risk 
of asthma (64, 65), and others have found no association (54, 62), or even an inverse 
association with a decreased risk of asthma (66).  
Previous studies have also reported that being born preterm (67-69) and with low birth weight 
(70-72) is associated with lung function deficits in child-and adulthood, whereas others have 
found no association (73, 74). As for asthma, the association between fetal growth and lung 
function has been less well studied. However, some studies have found an association 
between SGA and impaired lung function (75, 76).  
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Potential pathways 
Figure 5 illustrates potential pathways of the association between fetal growth and asthma 
and lung function. For instance, genetic factors play an important role in fetal growth (77-80), 
in asthma and lung function (31, 81-86). However, it remains unclear how genetic 
determinants for fetal growth and asthma and/or lung function are related, and whether 
reported findings on e.g. epigenetic modifications are causal or merely a response to an 
adverse intra- or post-uterine environment. Environmental factors in utero and/or in postnatal 
life that have been investigated as potentially important for fetal growth, asthma and/or lung 
function, include maternal smoking during pregnancy (87), vitamin D (52, 88, 89), air 
pollution (90-92), viral infections (93) and early allergen sensitization (94). It also seems 
possible that postnatal growth and obesity may be of significance for the development of 
asthma (95, 96) and lung function (76, 97). 
 
Figure 5. Potential pathways leading from adverse fetal and childhood exposures to growth 
adaptations and respiratory health outcomes.  
Major concerns regarding previous literature lie in the fact that birth weight, gestational age, 
and fetal growth are strongly correlated, and that it has been difficult to disentangle effects 
from these exposures. Although studies have controlled for confounders, residual 
confounding from factors that are difficult to measure, such as genetic susceptibility, diet 
during pregnancy, and socio-economic status, may still be a problem and may lead to 
spurious conclusions. Here, studies of twins may function as a tool to disentangle true effects 
from genetic and environmental confounding. In addition, studies of twins may allow 
investigating fetal growth independently of gestational age, due to the fact that twins are born 
at the same gestational age. Thus, a difference in birth weight within a twin pair may be 
regarded as difference in fetal growth. 
  
Environmental factors 
In utero 
In childhood 
Genetic susceptibility 
Epigenetics 
Growth  
Fetal growth 
Infant growth 
Childhood asthma 
Lung function 
At birth 
In childhood 
Respiratory disease  
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1.2.2 Antibiotics 
“One sometimes finds what one is not looking for” Sir Alexander Fleming  
The discovery 
The introduction of antimicrobial agents into general clinical practice denotes one of the 
milestones of medical advances in modern medicine. In 1928, Alexander Fleming became 
famous after discovering a mold identified as Penicillium notatum, in a Petri dish seeded with 
the bacteria Staphylococcus aureus, which actively killed the bacteria (98). After the 
discovery of penicillin, and during the last half of the 20
th
 century, a number of new 
antimicrobials came into clinical use, giving clinicians a variety of choices when treating 
many types of infectious diseases that had previously been deadly or caused major adverse 
health effects (99).  
Prescription patterns  
Figure 6 illustrates the consumption of antibiotics in outpatient care in different European 
countries (100). The first choice of antibiotics for all European countries is penicillin, but the 
proportion of different types of penicillin varies (101). While the consumption of antibiotics 
has slowly decreased in Sweden during the last decade, the consumption of antibiotics 
globally has increased (102).
 
Figure 6. Total outpatient antibiotic use in 33 European countries in 2009. DID – defined daily doses 
per 1000 inhabitants per day; Light blue – Penicillins; dark green – Cephalosporins; purple – 
Macrolides; orange – Quinolones; pink – Tetracyclines; light green – sulphonamides; dark blue: 
urinary antiseptics; yellow – others. From Adriaenssens N, et al. J Antimicrob Chemother. 2011;66 
Suppl 6:vi3-12. Reproduced with permission from Oxford University Press. 
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Notably, the effectiveness of antibiotics against bacterial infections has been reduced as 
bacteria have developed ways of staying alive and becoming resistant to antibiotics (103). As 
the majority of antibiotic prescriptions are issued in outpatient care, a reduction in these 
prescriptions would have a large impact on the total use of antibiotics (101, 104). Acute 
respiratory infections are commonly treated with antibiotics in outpatient care (105), and 
children contribute to a key part of the prescriptions filled (106). Yet, acute respiratory 
infections in children are most often viral or of non-severe bacterial etiology (105), and the 
effectiveness of antibiotics in these cases is limited. 
Antibiotics and asthma 
The increasing use of antibiotics (100) has co-occurred with the rising prevalence of 
childhood asthma (9). This has led to a surge of observational studies investigating the 
potential harmful role of exposure to antibiotics in fetal and early life and subsequent 
development of childhood wheeze and asthma (107, 108). In 1998, Farooqi and Hopkin 
suggested that exposure to antibiotics in early childhood increases the risk of asthma (109). 
Not long after, Benn and colleagues reported that exposure to antibiotics in fetal life increases 
the risk of subsequent childhood asthma (110). So far, the majority of studies investigating 
the association between antibiotic exposure and asthma have found an increased risk of 
asthma (107-117); however, evidence for a causal association is lacking.  
Potential mechanisms 
The ‘hygiene hypothesis’, proposed by Strachan in 1989 suggests that the lack of microbial 
exposure, as a result of very hygienic conditions in early life, may have an impact on the 
balance of the immune system, leading to the development of allergic diseases (118). With 
the identification of T-helper cells type 1 (Th1) and type 2 (Th2), the theory became plausible 
as some environmental factors seemed to be able to induce an allergy-protective immune 
response by Th1 cells (119). Based on the hygiene hypothesis, it is rational to propose that 
the increase of early life exposure to antibiotics reduces impact of microorganisms and 
subsequently promotes allergic immune responses. For instance, antibiotics have been 
suggested to induce a Th2-skewed response, driving the immune system towards an allergic 
pathway (120).  
In 2005, Mairi Noverr and Gary Huffgnale presented an alternative interpretation of the data 
supporting the ‘hygiene hypothesis’, namely the ‘microflora hypothesis’, which proposed that 
alterations in the gastrointestinal microbiota due to antibiotics may disturb mechanisms of 
immunological tolerance in the mucosa, leading to an increased risk of allergic airway 
disease in genetically susceptible individuals (121).  
Different possible biological mechanisms have been suggested for the association between 
fetal exposure to antibiotics and childhood asthma. It has been hypothesized that maternal 
antibiotic treatment could activate a disease process in perinatal life in susceptible 
individuals, or that maternal antibiotics may alter the microflora colonization patterns in 
neonatal life, or that inflammation due to a maternal infection could modulate the fetus’ 
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developing lungs, leading to subsequent asthma (60, 122-124). However, clear confirmed 
biological explanations are lacking.  
Despite these biologically plausible links between antibiotic use and asthma, it has also been 
suggested that antibiotics may not cause asthma at all, but that the observed associations have 
been due to confounding by indication or reverse causation. This could be the case because of 
respiratory infections and diagnostic uncertainty in the nature of wheeze in young children 
(125) or attributable to genetic predisposition to both infection and asthma (122, 126). The 
association could also be due to residual confounding (127). Studies of siblings may function 
as useful tool to disentangle potential causal effects due to antibiotics from effects due to 
genetic and environmental confounding, as siblings may be differently exposed to antibiotics, 
but at the same time share genes, early life environment and parental factors (127). 
1.3 TWIN AND KIN  
Twins have stimulated myths and stories for centuries, from Greek mythology to 
Shakespeare’s “Comedy of errors”. Sir Francis Galton noted in 1875 that the study of twins 
may allow “to weigh in just scales the respective effects of nature and nurture” (128) and 
twins have continued to intrigue and inspire scientists, owing to the possibility to partition the 
observed variance of a trait into genetic and environmental variation. As an extension of twin 
studies, methods comparing full- and half siblings within families, cousins, or offspring of 
twins or siblings, have been developed (127). In this thesis, we take advantage of the unique 
features of twins and siblings to further assess causality of previously suggested associations. 
In Sweden, about 110,000 children are born each year and each woman gives birth to 
approximately two children, meaning that most children will have a sibling at one point. 
Approximately 3% of the births are multiple births, the majority of which are twin births. 
Twinning occurs as a result of the implantation and maintenance of two embryos and can 
happen spontaneously in two ways; either through an early splitting of one fertilized egg 
(zygote) or through separate fertilization of two eggs (129). Approximately one-third of all 
twins come from one fertilized zygote and are accordingly called monozygotic (MZ), 
whereas the remaining two-thirds stem from two zygotes and are thus called dizygotic (DZ). 
During the last decades, the rate of twinning has increased around the world, which is thought 
to be due to increasing maternal age at first child and assisted reproductive therapies (130).  
Differences in fetal growth 
Compared to singletons, twins will need to share both the space and supply line from the 
mother in utero, where the foundation for this sharing depends on the placentation (129). An 
embryo is enclosed in the inner amnion membrane, and the outer chorion, which is the 
connection to the maternal circulation via the placenta. Embryos that are separate, as is the 
case for singletons and DZ twins, will develop their own membranes and are able to form 
individual placentas (although some of the DZ placentas will fuse together). MZ twins may 
also have their own placenta if the division of the fertilized egg occurs before the formation 
of the chorion. If the division of the egg happens later, the MZ twins will have their own 
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amnion membrane, but there will only be one chorion and thus one placenta to be shared by 
the twins. In rare cases, the MZ twins will share both amnion and chorion (129).  
Up until the 3
rd
 trimester, the prenatal growth of twins is commonly described to be similar to 
that of singletons (131). From then on it has been suggested that the twin growth velocity is 
down-regulated as a response to the environment when the combined size of the fetuses goes 
beyond a certain threshold (132). In a cohort of twins, fetal genes, maternal factors and 
placental function are expected to influence the variation in fetal growth. Zygosity and 
chorionicity further influence fetal growth, which probably is a reflection of the importance 
of placentation and the location of the chord insertion (129). Compared to singletons, the 
unique constraints on twins, due to their sharing of space and supply line, likely overshadow 
most other influences on growth. The variation in growth between unrelated twins is likely 
influenced by the same determinants as described for singletons, i.e. the individual growth 
potential and supply line supporting it. 
Shared genes within families – genetically informed samples 
A fertilized human egg should contain a nucleus with our genome separated into 46 
chromosomes divided into 23 pairs, where one chromosome in each pair comes from the 
mother and the other from the father. Since we get half of our chromosomes from our 
mothers and half from our fathers, singleton full siblings will thus share, on average, 50% of 
their segregating genes, as will DZ twins that stem from two separately fertilized eggs. Half 
siblings will consequently share approximately 25% of their segregating genes. On the other 
hand, MZ twins that stem from one fertilized egg will share 100% of their genes. While the 
genetic setup is expected to be the same for MZ twins, epigenetic modulations of the DNA 
(potentially influencing how genes are expressed) are unique for the individual, thus MZ 
twins also differ to some extent (133). As a result of the genetic similarities and 
dissimilarities between twins and siblings it is possible to partition the observed variance of a 
trait into genetic and environmental variation.  
Unique and shared environment 
In twin and siblings studies, the environmental variance of a trait is commonly divided into 
unique and shared environment. The shared environmental factors are factors common to a 
twin pair or siblings in a family, such as socioeconomic status, home environment, 
upbringing, and health seeking behavior. These are factors that make twins in a twin pair or 
siblings in a family more similar. The unique factors are those that each individual 
experiences throughout life, such as exposure to certain medications and treatment 
procedures, infections or other medical conditions, personal tobacco usage, physical activity 
and diet. A difference in shared intrauterine environment for MZ and DZ twins is largely 
ascribed to the MZ twins who share a placenta, which have a greater potential for inter-fetal 
exchange (through vascular anastomoses).  
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Box 1. A note on DAGs  
The DAG can be applied to various analyses, for example, a study of the association between an 
exposure (X) and an outcome (Y). A directed arrow between these two variables indicate that X 
may cause Y, but the arrow does not say anything about whether the association is positive or 
negative, or about strength of the association. 
A known and measured factor that is a common cause to the exposure and the outcome is 
defined as a confounder (denoted Z).  A factor that lies in the causal pathway between the 
exposure and the outcome is defined as a mediator (denoted M). There are almost always 
mediators on the causal pathway, but this does not indicate that the exposure is not causal.  
When the exposure and the outcome are common causes for a third factor (a common effect), 
this factor is called a collider (denoted C).  Pathways through colliders are closed, unless the 
collider is adjusted for which will then open the path and potentially cause spurious associations.  
 
 
1.4 CAUSAL INFERENCE IN OBSERVTIONAL STUDIES 
Causal inference is the procedure used to help draw conclusions whether an occurrence of an 
effect is caused by an exposure or intervention or only associated with it (134). By 
randomizing individuals to different interventions in an experimental study, the investigator 
aims to control all parameters of the study, including the timing of the exposure in relation to 
the outcome. This means that one can, with rather high certainty, assume that any observed 
association between the exposure and the outcome was caused by the intervention. When 
randomized controlled trials are not possible due to economical, practical or ethical reasons, 
observational epidemiological studies can be used to investigate associations between 
exposures and outcomes, i.e. to identify potential risk or protective factors for a disease. 
However, due to the fact that practically all environmental exposures are non-randomly 
assigned in the population (for instance, some people are more prone to perform regular 
physical activity whereas some are more prone to smoke) one has to ask if associations seen 
in an observational study are causal or induced by problems inherent to the study design. 
When assessing causality in an epidemiological study, Directed Acyclic Graphs (DAGs) may 
be used (Box 1) (135).   
1.5 INTERNAL VALIDITY 
An epidemiological study can be viewed as an exercise in measurement, where the goal is to 
obtain an accurate result, with as little error as possible. Validity distresses how closely we 
X Y 
Z 
M 
C 
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Birth weight Asthma 
Smoking during pregnancy  
measure what we intend to measure. Bias, a term used to describe any type of systematic 
error in a study, can infiltrate epidemiological studies from numerous directions and threaten 
the internal validity of the study (134). Efforts to avoid systematic errors include appropriate 
study design, data collection and analysis. In this thesis, bias will be classified in three broad 
categories; confounding, selection, and information bias.   
1.5.1 Confounding 
Mere associations do not mean causality; thus, even though a specific exposure and a specific 
outcome may be associated, the exposure might not cause the outcome. Confounding of an 
association is defined as when there is a common cause of exposure and outcome  and can be 
thought of as a mixing of effects (134). For a factor to be a confounder, it cannot be an effect 
of the exposure, thus acting as a mediator in the causal pathway. Confounding can cause bias 
in either direction, i.e. an over- or underestimation of the effect. In some cases, the bias from 
confounding can be strong enough to reverse the supposed direction of an effect (136).  
Figure 7and 8 display two examples of confounding. In the first example, a measure of the 
confounder maternal smoking can be relatively easily identified, for instance in the Medical 
Birth Register or through questionnaires (even though the validity of the variable has to be 
taken into consideration). In the second example, information on the confounder respiratory 
infections could potentially be found in medical records or collected through parental 
questionnaires, or identified by using different groups of antibiotics as a proxy measurement 
for the type of infection that is assumed to be treated.  
 
 
 
 
  
 
 
If confounding is not controlled adequately in the study design by e.g. randomization or 
matching, it is possible to adjust the association for this variable, thereby closing the pathway 
from the exposure to the outcome through the confounder. There are standard methods for 
this, such as stratification which means estimating the association separately for different 
levels of the confounder. One can also use regression model adjustments which are used to 
find estimates averaged over the different levels of the confounder. As the layers of 
confounding are left behind, one approaches deeper causal understanding of the underlying 
biology. 
Antibiotics Asthma 
Respiratory infections Figure 8. The exposure antibiotics, the 
outcome asthma and the confounder 
respiratory infections. This type of 
confounding is called confounding by 
indication. 
 
Figure 7. The exposure birth weight, the 
outcome asthma and the confounder maternal 
smoking during pregnancy.  
 15 
 
Another source of confounding comes from variables that are shared within families, 
including genetic and environmental factors, from now on denoted as familial confounding. 
Two examples of familial confounding in this thesis are displayed in Figure 9 and 10. 
 
 
 
 
 
 
 
 
 
 
In these examples, diet patterns and genetic predisposition are variables that are difficult to 
measure with high validity in observational studies, and are therefore often left out in 
analyses and referred to as residual or unmeasured confounding. Studies that ignore these 
types of unmeasured genetic and environmental familial confounders may therefore produce 
biased inference (127).  
1.5.2 Selection bias 
The term “selection bias” is commonly applied to biases resulting from inappropriate 
selection of controls in case-control studies, from differential loss-to-follow up in longitudinal 
studies, volunteer bias, healthy-worker bias, and nonresponse bias (134). The source of those 
biases arise from conditioning on a common effect (Figure 11) (137). Non-random selection 
in itself does not automatically result in selection bias, but for selection bias to arise, the 
intended exposure as well as outcome of the study must be associated with the common 
effect, e.g. participation status (137).  
 
 
 
 
Figure 11. An association between birth weight and asthma is introduced by conditioning on 
participation in the study if this is an effect of a cause of birth weight through socio-economic status, 
and of a cause of asthma through family history of asthma.   
1.5.3 Information bias 
When the exposure, outcome or other variables in the model, are not measured perfectly, 
information bias (misclassification) may occur (134). If the misclassification of the exposure 
is random with respect to any other variable in the model, or vice versa, the misclassification 
is referred to as non-differential. Non-differential misclassification of the exposure is 
Respiratory infection Asthma 
Genetic predisposition Figure 10. The exposure respiratory 
infection, the outcome asthma and the 
confounder genetic predisposition – 
genetic confounding.  
 
Birth weight Asthma Participation 
Socio-economic status Family history of asthma 
Figure 9. The exposure birth weight, 
the outcome asthma and the 
confounder diet during pregnancy – 
environmental confounding. 
Birth weight Asthma 
Diet during pregnancy  
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regarded to lead to an attenuation of the true effect. Non-differential misclassification of the 
outcome will lead to larger variability in the data. If misclassification between comparison 
groups differs systematically (differential misclassification), the bias can go in either 
direction.  
A specific type of information bias is the issue of reverse causality, which represents the 
chicken and egg dilemma. When an exposure is time-varying, or when the onset of a disease 
(the outcome) is difficult to measure, it can be difficult to ascertain if the exposure preceded 
the outcome or if the outcome actually came first. Figure 12 illustrates how the outcome of 
asthma (Y) precedes the exposure of antibiotics (X). For instance, early symptoms of asthma 
(Y*) such as wheezing, may be mistaken for a respiratory infection, leading to antibiotic 
treatment. When the symptoms don’t disappear with antibiotic treatment, the subject might 
seek health care again and then given a diagnosis of asthma (Y).  
 
 
 
Figure 12. DAG illustrating the issue of reverse causality, where early symptoms of asthma precede 
antibiotic treatment.  
Another common type of information bias is recall bias, a type of differential 
misclassification, which occurs when a subject is asked about the exposure after the disease 
has occurred, as in case-control studies or retrospective cohort studies. For instance, it has 
been suggested that acetaminophen use in early childhood is associated with an increased risk 
of asthma (138). However, it has been questioned whether this is a causal association or not, 
as e.g. parents to children with asthma may be more or less likely to report early use of 
acetaminophen compared to parents to children without asthma, which could then induce a 
spurious association. Recall bias is distinct from the more general problem of remembering 
and reporting events, which happens to all people and tends to be a non-differential 
misclassification. 
1.6 EXTERNAL VALIDITY 
Systematic errors determine the internal validity, and as the “internal” indicates, this concerns 
only the subjects studied. If the subjects under study are representative of the population we 
want to make inference about, the target population, then findings may be generalizable to 
this population as well. This is referred to as external validity or generalizability. The issue of 
generalizability of findings in twins compared to singletons and families with siblings 
compared to families with only one child will be discussed later. 
  
  X  Y Y* 
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2 AIMS 
 
Much focus has been put into the idea of how our future may be programmed in utero or 
early in childhood. For instance, low birth weight and exposure to antibiotics in fetal life 
and early childhood have been suggested to increase the risk of asthma or lung function 
impairment in childhood. Twin- and sibling comparisons can help account for confounding 
factors shared within families and shed light on potential causal pathways. Furthermore, to 
be able to study asthma in register-based research, a valid measure of the disease is needed.  
Specifically, we aimed to: 
 investigate if low birth weight, as a proxy for fetal growth restriction in twins, was 
associated with an increased risk of asthma in childhood, independent of gestational 
age and familial factors (Study I)  
 
 examine if fetal growth restriction was associated with impaired lung function in 
childhood, independent of gestational age and familial factors, and whether the 
potential association differed in individuals with and without asthma (Study II) 
 
 assess whether asthma medication reported in the Swedish Prescribed Drug Register 
could function as a proxy for asthma and evaluate if asthma diagnoses in the National 
Patient Register fulfilled predefined criteria of asthma (Study III)  
 
 study if antibiotic exposure in fetal life and early childhood was associatied with 
subsequent childhood asthma, independent of familial factors (Study IV) 
 
 
  
 18 
 
3 MATERIAL AND METHODS 
3.1 AT A GLANCE 
 
 Population Material Method 
I 10 918 twins, 9- or 12 
years old, included in 
CATSS  
Exposure: Birth weight, 
gestational age and fetal growth 
from the MBR 
Outcome: ‘Asthma ever’ from 
parental interview in CATSS 
Confounders from CATSS and MBR 
Generalized estimating 
equations with the logit 
link and exchangeable 
covariance structure 
within pairs for the full 
cohort analyses 
(between-family) and 
conditional logistic 
regression for the within-
twin pair analyses 
II 576 twins, 9-14 years 
old, included in 
STOPPA  
Exposure: Birth weight, 
gestational age and fetal growth 
from MBR 
Outcome: Lung function measures 
from dynamic spirometry  
Effect modifier: Current asthma 
from parental questionnaire in 
STOPPA 
Confounders from MBR and 
parental questionnaire in STOPPA 
Linear regression with 
robust sandwich 
estimator for the full 
cohort analyses 
(between-family) and 
linear regression with 
fixed effects estimator for 
the within-twin pair 
analyses 
III Samples of individuals 
with a history of 
asthma* medication 
or diagnosis aged 0-17 
years (study base, 
N=81 580) 
Asthma medication (ATC: R03) 
from the SPDR and asthma 
diagnoses (ICD 10: J45) from the 
NPR, and medical records for 
1710 individuals from 1117 health 
care units around Sweden 
Descriptive statistics in 
terms of period 
prevalence, incidence, 
positive predictive value, 
and proportions  
IV 493 785 children born 
to women pregnant 
between July 2005 
and December 2010, 
followed from start of 
pregnancy to school-
age 
 
Exposure: Systemic antibiotics 
(ATC: J01) from SPDR 
Outcome: Asthma on the basis of 
an asthma diagnosis in the NPR 
(ICD 10: J45) in combination with 
asthma medication (ATC: R03) in 
the SPDR. This outcome was 
validated in study III.  
Confounders from LISA, MBR and 
NPR  
Cox proportional hazard 
model with robust 
sandwich estimator for 
the full cohort analyses 
(between-family) and 
stratified Cox proportional 
hazard model for the 
within-sibling analyses 
  
                                                 
*
 Please note that study III also includes a validation of asthma in adults and of eczema medication as a proxy for 
eczema in childhood. However, as the focus of this thesis has purposely been on childhood asthma, these parts of 
the study are only mentioned briefly in the method section and further information can be found in the 
manuscript. 
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3.2 PERSONAL IDENTIFICATION NUMBER 
Sweden has a long history of holding registers and producing population statistics. In 1686, 
the Swedish church began to register parish members into local registers (church books), 
which enabled the church and the Swedish state to keep a population census, enroll 
individuals to the army, and for tax issues (139).  
In 1947, personal records including information on date and place of birth, sex, and address 
were established for all individuals who were registered in a local parish register and each 
individual was assigned a personal identification number (PIN). In 1991, the responsibility of 
the local parish registers was moved to the local tax offices, and from then onwards the 
responsibility of the PIN was taken care of by the National Tax Office.  
When a child is born in Sweden, the obstetric department, the responsible midwife (for births 
outside the hospital), or the parents (if no midwife is present at the delivery), are obliged to 
report the birth to the National Tax Board within one month after the delivery. Historically, 
the newborn child has been assigned a temporary number at the delivery ward and then the 
PIN was sent to the home within a few days. However, since a few years back, newborns are 
now given the PIN directly in the delivery ward through an automatic linkage between the 
National Tax Board and Obstetrix, which is the electronic health record system used by more 
than 90% of the maternity and delivery units in Sweden.  
The PIN consists of a six-digit birth date and a four-digit identification number. It is a unique 
identifier and the basis for all public administration in Sweden. Thus, all administrative and 
other registers are indexed by this number. This enables unambiguous linkage between 
national registers and other study specific or clinical data.  
Immigrants who become permanent residents or intend to stay in Sweden for at least one 
year, also receive a personal identification number. Immigrants, who do no not fulfill this 
condition, but who use the Swedish social security system are assigned a coordination 
number by the National Tax Board. Individuals with coordination numbers are not included 
in national demographic or health registers. Hence, residents with coordination numbers 
will not be sampled in national register-based studies in Sweden.  
3.3 DATA SOURCES 
3.3.1 Registers 
All four studies in this thesis take advantage of Swedish national population-based 
registers. National registers containing primarily demographic information are kept by 
Statistic Sweden, whereas the population-based national health registers are kept by the 
National Board of Health and Welfare (NBHW). The Swedish Twin Register (STR) is 
hosted by the Department of Medical Epidemiology and Biostatistics at Karolinska 
Institutet.  
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Total population register 
The Total Population Register (TPR) was established by Statistics Sweden in 1968, when 
large sections of the local population registers were computerized (140). Information on 
births, deaths, place of residence, civil status, migration, relations and citizenship are 
reported from the local tax offices to the National Tax Board, with a daily notification to 
the TPR.  
Multi-Generation Register 
The Multi-Generation Register (MGR) is part of the TPR and links all Swedish residents to 
their parents, allowing for identification of family constellations, including identification of 
full- and half-siblings and cousins (141). The register was established in the early 1990s’ 
and includes all individuals, so-called index persons, who have been registered in Sweden 
some since 1961. The register contains information on the index person’s personal 
identification number, and the personal identification numbers of biological or adoptive 
parents (Figure 12). Linkage between index persons and parents is possible if the parents 
were alive and a resident of Sweden when the personal identification number was 
introduced in 1947 or thereafter. Immigrated index persons are only linked to their parents 
if they immigrated with their parents before age 18. The register was used in Study IV to 
identify siblings.  
 
Figure 12. Graphic presentation of four generations in the Multi-Generation Register, where circles 
represents females and squares represents males. Different family constellations that can be identified 
from the register are suggested.  
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Longitudinal Integration database for Health Insurance and Labor Market Studies  
The Longitudinal Integration database for Health Insurance and Labor Market Studies 
(LISA), held by Statistic Sweden, includes information on employment, disposable income, 
education, and area of residence among other data for all individuals aged 16 years or older 
and registered in Sweden. The database presently holds annual registers since year 1990 
(142). Information from the register was used in Study IV, where the highest level of 
education for either parent was identified.  
Medical Birth Register 
Since 1973, all pregnancies resulting in a delivery have been reported by the delivering unit 
to the Medical Birth Register (MBR), kept by the NBHW. The information in the register is 
derived from four medical records; two records from the antenatal care of the mother, the 
delivery record and the record of the newborn infant examination. Records for a small 
percentage of all infants (approximately 2%) are missing completely; for others, the 
information is incomplete for example, due to missing data from antenatal-care clinics or 
pediatric wards (143). By linkage to registers provided by Statistics Sweden, information on 
the mother’s country of birth and education at the time of pregnancy are added to the MBR. 
Information regarding exposures and potential confounders was collected from the register 
and used in Study I, II and IV.  
National Patient Register 
The National Patient Register (NPR) was established in 1964 by the NBHW and is based 
on hospital discharge records (144). The register includes information on dates of 
admission and discharge, type of hospital department, whether the hospital visit was 
scheduled or not and the cause of hospitalization. The cause of hospitalization is further 
divided into primary and secondary diagnoses, coded at the time of discharge according to 
the current version of the Swedish translation of the International Classification of Disease 
(ICD) as determined by the WHO. The diagnosis codes are entered more or less free hand 
by the attending physician into the register, meaning that data withdrawals from the register 
by researchers may include spelling mistakes and data irregularities. Nevertheless, it has 
been estimated that more than 98% of the hospital visits have been reported correctly (145).  
From the time of its establishment, the register has expanded from only including data from 
six counties (out of 21), to covering approximately 85% of the discharges in 1983, to 
having complete national coverage from January 1987 and onwards. In 2001, outpatient 
visits from hospital-based clinics began to be reported as well and today, approximately 
80% of the outpatient visits are recorded. However, data from primary health care clinics 
are not included in the NPR. Information from the register was used in Study II, III and IV. 
Prescribed Drug Register 
In July 2005, the Swedish Prescribed Drug Register (SPDR), the newest population-based 
health register held by the NBHW, was established. The register contains data on all 
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dispensed prescribed medications from outpatient care and in the primary health care for all 
Swedish residents (146). The register includes information on the dispensed item including 
dosage, expenditure and reimbursement, age, sex and place of residence of the patient, 
prescription and dispensing date, a prescriber code and the prescriber’s profession. All 
drugs are classified according to the Anatomical Therapeutic Chemical (ATC) 
classification system (147). However, the register does not include data on over-the-counter 
(OTC) drugs, drugs used in hospitals or drugs that were prescribed but not dispensed. 
Furthermore, the indication for the drug is only available if noted by the physician on the 
prescription and then only available in free text. Information from the register was used 
primarily in Study III and IV. 
3.3.2 Twin cohorts 
The STR was established in the late 1950s’ with the intention to study the health effects of 
smoking and alcohol, with the capacity to control for genetic liability for disease (148). The 
register includes information on twins born in Sweden since 1886, which at present is more 
than 95,000 twin pairs (148, 149). The twins under study in this thesis were born from 1992 
and onwards and are included in the Child and Adolescent Twin Study in Sweden (150) and 
the Swedish Twin study On Prediction and Prevention of Asthma (151). 
The Child and Adolescent Twin Study in Sweden 
In Study I, the study population was derived from The Child and Adolescent Twin Study in 
Sweden (CATSS) which is an ongoing longitudinal twin study targeting all twins born in 
Sweden since July 1992. Since 2004, the STR has systematically approached parents of 9-
year old twins with an invitation to participate in a telephone interview regarding their 
children’s somatic and mental health and social environment. During the first three years of 
the study, twins aged 12 years (born 1992-1994) were also included. By March 2014, 
parental interviews concerning ~ 23 900 twins have been completed, with an overall 
response rate of 70% (149). Analyses of the differences between non-responders and 
responders, based on a merge of data from approximately 11,000 twins from CATSS, 
Statistics Sweden, and NBHW, have shown that non-responders more often belong to a low 
socio-economic stratum and have more neuropsychiatric diagnoses such as attention-deficit 
hyperactivity disorder and autism spectrum disorder (150). 
Zygosity in CATSS is determined by DNA (in saliva) or by using answers to questions 
about similarity such as “Are your twins like two peas in a pod, or more like siblings in 
general?”, which have shown an accuracy of around 95% (148). Building on the 
recruitment of CATSS, several follow-ups and extensions have been initiated, such as a 
follow-up at age 15 and 18, and other cohorts with the aims to study more disease specific 
questions (149).  
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The Swedish Twin study On Prediction and Prevention of Asthma  
One of the extension studies from CATSS is the Swedish Twin study On Prediction and 
Prevention of Asthma (STOPPA) (151). STOPPA was initiated in May 2011 and 
completed in June 2014. Based on questions on asthma and wheezing (26) included in the 
CATSS interview, an algorithm was created to identify twins discordant and concordant for 
a history of asthma/wheezing. MZ and DZ same-sexed twins aged 9-14 years old at the 
invitation, were invited with their parents to a clinical examination. The twins were 
examined in collaboration with pediatric allergy and asthma clinics in Gothenburg, 
Linköping, Karlstad, Umeå, Växjö, Lund, and at Lomma Primary Health Care Centre. In 
Stockholm, the twins were examined at test centers at Karolinska Institutet (Figure 13). At 
the examination the twins and parents answered a questionnaire each, and the twins were 
thereafter invited to measure their weight and height, their lung function by dynamic 
spirometry and fractional exhaled nitric oxide, as well as give blood-, saliva-, urine- and 
fecal samples. In total, 752 twins were included in STOPPA, with a response rate of 
approximately 52% from the first contact by a research nurse over telephone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. The location of the clinical examinations in STOPPA. 
In Study II, objective measures of lung function from spirometry were used. The individual 
was asked to take the deepest breath possible and then exhale into a sensor as hard as 
possible, for as long as possible. The procedure was repeated at least three times before and 
after inhalation of a short-acting bronchodilator. The procedure and evaluation of spirograms 
were performed in accordance with guidelines by the American Thoracic Society/European 
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Respiratory Society (ATS/ERS) recommendations  (21). The all-age reference values were 
used to calculate z-scores and lower limits of normal (23). 
3.3.3 Medical records  
Medical records are mainly an important tool for health care personnel to secure patient 
safety and all health care, public or private, that is provided is required by law to be 
documented in the medical record. Nowadays, the majority of the medical records are 
electronic and the patients’ medical history is stored in databases based on their PIN. In 
addition to being a tool in the clinicians’ daily practice, the medical record may also be used 
for evaluation of health care units, in legal contexts, as reference material, and for quality 
control in a research setting. In Study III, patient medical records were identified based on the 
PIN in combination with the name of the health care unit, and used to validate information on 
asthma medication in the SPDR and diagnosis in the NPR.  
In short, for the validation of asthma medication as a proxy for asthma, individuals fulfilling 
criteria for asthma medication in the SPDR (Figure 1 in paper III) without a diagnosis of 
asthma in the NPR were identified, and medical records for a random sample of these 
individuals were requested and reviewed (Figure 14). For the assessment of asthma 
diagnoses in the NPR, individuals with a diagnosis in the register, independent of their 
history of asthma medication, were identified and medical records for a random sample of 
these individuals were requested and reviewed.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Linkage between the Swedish Prescribed Drug Register (SPDR) and National Patient 
Register (NPR), to identify individuals to be included in the validation of asthma medication as a 
proxy for asthma, and assessment of asthma diagnoses in the NPR. 
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3.4 BETWEEN- AND WITHIN-FAMILY DESIGN 
As has been previously discussed, an association between an exposure and an outcome does 
not automatically imply causality. Other factors may influence the association and these 
factors can only be adjusted for if they are known and measured. Unmeasured and non-
measurable variables may induce a spurious i.e. non-causal association between two 
variables, and lead to incorrect interpretation and conclusions.  
The first step is to acknowledge that confounding might be present, and the second step is to 
adjust for the confounders, which can be problematic when dealing with unmeasured 
confounders. When the confounder is shared within a twin pair or within siblings in a family 
(familial confounding), as in the case with genetic alleles or certain behaviors, a possibility 
for better inference arises (127). 
In a traditional between-family analysis, individuals from different families are compared 
(upper panel, Figure 15). In a within-family analysis, individuals (twins/siblings) are 
compared with individuals from the same family, making it possible to study the association 
between an exposure and an outcome, while adjusting for familial factors (lower panel, 
Figure 15).  
 
Figure 15. Between-family (upper panel) and within-family (lower panel) analysis.  
Adjusting for familial factors is possible due to the fact that MZ twins share all of their genes, 
while DZ twins and full siblings share on average half of their segregating genes. 
Furthermore, twins and siblings share parental factors and intrauterine exposure to some 
extent. If associations seen in a cohort of twins/siblings remain when non-affected twins/ 
siblings are used as controls to the affected individual, then factors unique to the individual 
are assumed to be involved in the underlying causal pathway. In contrast, if the association is 
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attenuated or disappears, then factors common to the twins/siblings are involved. Thus, 
within-twin or within-family studies are based on individuals who are not randomly assigned 
to a setting, but instead take advantage of ‘natural experiments’ based on family 
constellations. Comparisons of findings within MZ versus DZ twin pairs can further provide 
insight into the role of genetic factors. If there is no difference in the strength of the 
association between the exposure and outcome between MZ and DZ twins of same sex, then 
the association is thought to be independent of genetic factors.  
In Study I, II and IV the study participants are first regarded as any other cohort population, 
and associations are investigated between individuals independent of their family 
constellation. Analyses are controlled for known and measured confounders by including 
them in the models. Secondly, to gain more insight about the role of early life risk factors for 
subsequent childhood asthma, we take advantage of each individual’s family constellation to 
investigate family-adjusted estimates: within-twin pairs and within-sibling group estimates.  
 
  
 
 
 
3.5 STATISTICAL ANALYSES 
Random error 
Random error is the variability in data that we cannot explain (134). Random error may stem 
from random biological processes, but could also stem from sampling. The random 
variability will in turn affect the precision of the sample estimation. Statistical analyses of 
epidemiological data attempt to assess variability in the data in an effort to distinguish chance 
findings from true results that might be replicated upon repetition of the work. Any study 
with a study population smaller than infinitely large would only give an estimation of the true 
value. The random error can be reduced by increasing the study population size.  
Handling of clustered data 
While the degree of similarity in twins and siblings tend to be the objective in within-twin or 
within-sibling studies, it is also a feature that calls for special care in the methods used for 
statistical inference. In most statistical analyses, one fundamental assumption is that the 
observations in a model are independent from each other. Assuming the opposite, when 
observations are in fact positively correlated as with twins and siblings, can lead to 
overestimation of the statistical information of the data with too narrow confidence intervals 
or too low P-values (152). In the statistical methods used for Study I, II and IV, the size of the 
X
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Figure 16 illustrates a simple situation of familial confounding, 
where sub-index 1 represents twin/sibling 1 and sub-index 2 
represents twin/sibling 2. In this situation, estimations of the 
association between X and Y, without adjustment for the 
unknown confounder U, would produce a biased estimate. If U 
is an unmeasured or non-measureable shared familial 
confounder, within-family adjustments may be used. 
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correlations between individuals (twins and siblings) are not of interest on their own, but 
rather viewed as nuisance factors that need to be accounted for. 
3.5.1 Study I & II 
As a first step in Study I (CATSS), the association between the exposure variables birth 
weight, gestational age, and birth weight for gestational age as a measure of fetal growth (by 
using SD scores (SDS) for birth weight by gestational week and sex) and the outcome 
variable ‘asthma ever’ (yes/no) was investigated in the full cohort of twins. The proc genmod 
procedure (which applies generalized estimating equations (GEE)) in SAS was implemented 
with the logit link and the exchangeable covariance structure. GEE is one method to handle 
clustered data and was therefore used to account for dependences within-twin pairs. The 
exposures were both assessed as categorical and continuous variables.  
Firstly in Study II (STOPPA), the associations between the same exposure variables as in 
Study I and continuous measures of lung function (FEV1, FVC, FEV1/FVC and post 
bronchodilator change in FEV1) were investigated with linear regression and the sandwich 
estimator of standard errors to account for clustering within-twin pairs. We also investigated 
whether the exposure variables influenced asthma, which subsequently influenced lung 
function (asthma acting as a mediator), or if the observed effect of the exposures on lung 
function differed in those with and without asthma (asthma acting as an effect modifier), by 
including asthma as a covariate (test of mediation) and as an interaction term with the 
exposure variables (test of effect modification), in the full cohort analyses. 
In a second step of Study I and II, within-twin pair analyses were performed, using 
conditional logistic regression in Study I and linear regression with the fixed-effects estimator 
in Study II. In the sample produced by twin pair matching, the regression analyses estimates 
the effect (change in log-odds of asthma or change in z-score in lung function) of the 
difference between two observations in the strata. Thus, a continuous measure of birth weight 
will estimate the linear effect of the within-twin pair difference in birth weight. In Study I, the 
odds ratio were reported in relation to 1000 g negative deviance in birth weight from the twin 
pair mean, while in Study II, the coefficient corresponded to a 500 g negative deviance from 
the twin pair mean.  
For more information on specific confounders and effect modifiers included in the models, 
please see papers I and II.  
3.5.2 Study III 
In Study III, the period prevalence of asthma medication (and/or eczema medications) was 
estimated as the proportion of individuals in the Swedish population for whom medication 
was dispensed during the year 2008. The nominator (number of drug users in 2008) was 
retrieved from the SPDR and the denominator (number of individuals within the age span 
during 2008) from Statistics Sweden.  
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Incidence estimates were based on all new users of asthma medication between 2008 and 
2009 and estimated person-time was based on population data from Statistics Sweden. The 
period of 2008-2009 was based on the waiting-time distribution. The waiting-time 
distribution, is a frequency distribution of first time occurrences of medication use within a 
time window, and essentially addresses when users of a specific medication will first appear 
inside a time window, when all information outside the defined time window is disregarded 
(153). For medication intended for chronic treatment, current users will generally be captured 
in the beginning of the time window. The distribution graph will eventually be dominated by 
new (incident) users after a certain period of time, depending on the type of medication and 
the expected time interval between dispensed prescriptions (Figure 2 in paper III). Except for 
information on incidence, seasonality of dispensed medication can also be assessed.  
Positive predictive value (PPV) was used to validate asthma medication as a proxy for 
asthmatic disease (Box 2). PPV was estimated as the proportion of children defined as having 
asthma according to a gold standard who also fulfilled asthma medication criteria 
(numerator), to all children fulfilling the asthma medication criteria (denominator). For 
information on specific medication criteria in different age groups, please see Figure 1 
paper III.  
Our gold standard for asthma was either having a record of an asthma diagnosis (ICD 10: 
J45) in the medical record, or fulfilling pre-defined criteria of asthma suggested by the 
Swedish Pediatric Society’s section for Allergy (Box 3) (154).  
 
 
Box 2. Validation measures 
  Gold standard  
  Yes No PPV=a/(a+b) 
Test outcome Yes a (true positive) b (false positive) Sensitivity=a/(a+c) 
 No c (false negative) d (true negative) Specificity=d/(b+d) 
     
Box 3. Asthma according to Swedish Pediatric Society’s section for Allergy 
 ≥ 3 obstructive periods before 2 years of age and/or;  
 ≥ 1 obstructive period after 2 years of age and/or;  
 ≥ 1 obstructive period independent of age when the child has ≥1 of the following: 
eczema, allergy, parents and/or siblings with asthma or no improvement between 
periods of respiratory tract infections.  
Children under two years of age with ≤ 2 asthma-like symptoms during respiratory tract 
infections and without symptoms between infections are defined as suffering from 
obstructive bronchitis. 
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Asthma diagnoses reported in the NPR were evaluated by calculating the proportion of 
individuals with an asthma diagnosis in the register that also were defined as having asthma 
according to criteria by Swedish Pediatric Society. 
A brief note: eczema medication as a proxy for eczema in children was also evaluated in 
Study III. The original plan was to use validated standardized criteria as the gold standard for 
eczema (155), but unfortunately the information in the medical records was too limited, thus 
leaving us with information only on given diagnoses in the medical record. Firstly, each 
medical record was reviewed to see if the child had been given the umbrella diagnosis of 
unspecific dermatitis, and secondly a specific diagnosis of dermatitis, namely eczema 
(L20), seborrhoeic dermatitis (L21) or contact (allergic (L23); non-allergic (L24)) 
dermatitis (L25).   
3.5.3 Study IV 
In Study IV, a Cox proportional hazard model, with the age of the child as the analysis time 
scale and the date of birth as time of origin, was used to investigate the association between 
exposure to antibiotics in fetal life and early childhood and asthma. The robust sandwich 
estimator was used to take clustering within the cohort into account.  
A stratified Cox proportional hazard model was used to investigate the association between 
antibiotics in fetal life and childhood and asthma, among siblings within families. In this 
model, each family has its own baseline hazard rate reflecting the family’s shared factors. 
The exposure comparisons (antibiotics vs. no antibiotics), are thus made within the family. 
The model takes differences in follow-up time into account. Hence, only sibling pairs 
discordant for antibiotics as well as asthma were informative for the analyses, i.e. contributed 
with information to the estimates. Indeed, to be informative, the sibling without asthma 
should have at least as long follow-up time as the sibling with asthma. 
To study the possibility of confounding by indication and reverse causation from respiratory 
infections, all analyses were performed with the exposure of antibiotics divided into three 
groups (117, 125): “any antibiotics”, “airway antibiotics”, and “urinary tract or skin and soft 
tissue antibiotics” as proxies for the indications of the treatments. We also included 
information on assumed exposure to “any antibiotics” within hospitals based on information 
on diagnoses reported in the NPR that we have previously shown to have a high correlation 
with antibiotic treatment (156).  
For details regarding confounders included in the models and information on sub- and 
sensitivity analyses, please see paper IV.  
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4 ETHICAL CONSIDERATIONS 
Ethics is about structuring, stimulating and maintaining a consciousness and a discussion on 
how to act. The applications of the Ethical Review Act (2003:460) that are important for 
studies included in this thesis are those addressing the handling of sensitive personal data, 
physical interventions of study participants, and collection of biological samples. As an 
underlying rule in the Ethical Review Act, all individuals that are involved in research shall, 
with few exceptions, be informed about the research, their participation in it, and have the 
option to participate or not. Consent to participate is only valid after the study subject has 
been properly informed about the study. If the study participant is a child, then it becomes 
more difficult to obtain adequate informed consent, as their ability to judge risk and assess 
consequences is limited and they can more easily be influenced by others. In the Ethical 
Review Act (18 §), children 15 years and older should be properly informed and give their 
own consent to participation. In younger children, the legal guardians of the child should be 
informed and give consent. However, the child should also be informed in a manner 
considered appropriate for their age group, and if the child opposes to the study, then the 
parents’ consent is not valid.  
In Study I, the children were 9 and 12 years of age, and the parents were thus informed and 
given the option to participate in the CATSS study including linkage to the national registers. 
In Study II, both children and parents were informed and asked for consent. All collected data 
(questionnaire, samples, objective measures) in STOPPA have been de-identified and the PIN 
replaced with a study number. The children and parents only consented to participate in 
STOPPA. In both CATSS and STOPPA, withdrawal from the studies is possible at any point 
in time.  
As previously described, informed consent applies to all research involving humans, with few 
exceptions. These exceptions include register-based studies, where data that have already 
been collected are used. In Study III, no informed consent was collected from the patient for 
whom we collected medical records. Instead, each head of the prescribing/treating health care 
unit was asked for permission, in accordance with the ethical permission of the study. All 
medical records were de-identified and replaced with a study number before the medical 
records were reviewed. To perform the study a large number of medical records had to be 
collected and we assessed that the benefit of informing the individual patient was smaller 
than the possible anxiety a request would involve. Furthermore, as asthma and eczema are 
common diseases in childhood often treated in the primary health care clinics, we evaluated 
the intrusion of integrity to be relative small.  
In Study IV, anonymized data for approximately half a million individuals were requested 
from the population-based demographic and health registers, and participation consent was 
not requested.  However, as the study examined a common exposure and outcome, the risk of 
identifying specific individuals within the cohort was regarded as small, as well as the risk of 
intrusion of the personal integrity.  
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5 MAIN RESULTS AND DISCUSSION 
5.1 STUDY I & II  
We found that the risk of childhood asthma increased with reduced birth weight, gestational 
age and fetal growth, in the full cohort of Study I. Similarly, we found that FEV1 decreased 
with reduced birth weight, gestational age and fetal growth, although not significantly, in the 
full cohort of Study II. We also found that post bronchodilator change in FEV1 increased with 
decreasing gestational age. No significant associations were found for FVC and FEV1/FVC. 
 
 
 
 
 
 
 
 
 
Figure 17. Asthma (left panel, Study I) and FEV1 (right panel, Study II) in relation to birth weight, 
gestational age and fetal growth in full cohort analyses.  
In the within-twin pair analyses, the association between birth weight, as a proxy for fetal 
growth in twins, and asthma (Study I) and FEV1 (Study II), remained.  
 
 
 
 
 
 
 
 
Figure 18. Asthma (left panel, Study I) and FEV1 (right panel, Study II) in relation to fetal growth 
within-twin pairs.  
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Furthermore, there was no significant difference in strength of the associations between MZ 
and DZ twins in Study I or in Study II, and no significant differences were found between 
preterm and term twins. 
In the full cohort analyses in Study II, we further tested whether birth weight, gestational age, 
and/or fetal growth influenced asthma which subsequently influenced lung function 
(mediation), or if the observed effect of the exposures on lung function differed in those with 
and without asthma (effect modification).  
We did not find any evidence for asthma being a mediator between the birth characteristics 
and lung function; however, while similar results were seen for individuals without asthma, 
an opposite pattern was found in those with asthma where FEV1 increased with decreasing 
birth weight and gestational age (p for interaction ≤0.05). 
 
Figure 19. Lung function in relation to birth weight, gestational age and fetal growth, in individuals 
with (right panel) and without (left panel) asthma.   
Please see paper II for further results regarding other lung function measurements, and 
sensitivity analysis excluding individuals with a history of respiratory distress syndrome 
(RDS) and bronchopulmonary dysplasia (BPD).  
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5.2 STUDY III 
The period prevalence of any asthma medication in the year 2008 was 7.5% in pre-school 
children (0-4.5 years) and 6.4% in school-age children (>4.5-17 years). Figure 20 illustrates 
the prevalence of filled prescriptions of different asthma medications during the same year. 
The incidence of pre-school asthma medication users was 3.70/100 person-years (95% CI 
3.66-3.74) and 2.12/100 person-years (95% CI 2.10-2.14) in school-age children.  
 
 
  
 
 
 
 
 
 
 
Figure 20. Prevalence of filled prescriptions of asthma medication during the year 2008. *Any of the 
following: β2 - inhaled β2-agonists; ICS - inhaled corticosteroids; LTRA - leukotriene receptor 
antagonists; β2-ICS - fixed combinations of β2-agonists and corticosteroids. 
When using an asthma diagnosis (J45) recorded in the medical record as gold standard, pre-
school children had a PPV of 68% for asthma medication as a proxy for asthma (Figure 21). 
Corresponding PPV in school-age children was 89%. The remaining 32% (pre-school) and 
11% (school-age) corresponded to acute bronchitis/bronchiolitis, chronic bronchitis and 
upper respiratory tract infections. When using asthma criteria by the Swedish Pediatric 
Society as gold standard, pre-school children had a PPV of 75% for asthma medication as a 
proxy for asthma, whereas school-age children had a PPV of 94%. In the assessment of 
asthma diagnoses in the NPR, 78% of the pre-school children and 99% of school-age children 
fulfilled the asthma criteria by the Swedish Pediatric Society.  
 
Figure 21. PPV for asthma medication as a proxy for asthma diagnosis in children, using either 
asthma diagnosis or asthma defined from criteria by the Swedish Pediatric Society, as gold standard.  
Please see paper III for results regarding eczema and asthma in adults.   
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5.3 STUDY IV 
We found significant associations between exposure to all groups of antibiotics in fetal life 
and childhood asthma in analyses of the full cohort of all children. In the within-sibling 
analyses, the associations disappeared.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Full cohort analyses (left panel) and within-sibling analyses (right panel) of antibiotic 
exposure in fetal life and subsequent asthma. 
We also found significant associations between any, airway and urinary tract/skin antibiotics 
in childhood and asthma in the full cohort analyses of all children. The highest risk of asthma 
was found in children exposed to airway antibiotics during the first six months in life. 
 
Figure 23. Full cohort analyses of airway (left panel) and urinary tract/skin (right panel) antibiotic 
exposure in early childhood and subsequent asthma. 
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In the within-sibling analyses, the association between urinary tract/skin antibiotics and 
asthma disappeared, and decreased markedly for airway antibiotics. 
 
Figure 24. Within-sibling analyses of airway (left panel) and urinary tract/skin (right panel) antibiotic 
exposure in early childhood and subsequent asthma. 
 
In full cohort analyses, using antibiotics during the first year of life as exposure and incident 
asthma from two years of age as the outcome, significant associations were found for all three 
groups of antibiotics. In the within-sibling analyses, the association disappeared for all groups 
of antibiotics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Full cohort analyses (left panel) and within-sibling analyses (right panel) of antibiotic 
exposure during the first year of life and incident asthma from two years of age. 
 
Please see paper IV for further results from sub- and sensitivity analyses.    
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5.4 INTERNAL VALIDITY 
5.4.1 Confounding 
The major advantages with within-family based designs, such as full-sibling comparisons and 
twin-comparisons, include the possibility to account for all genetic and environmental 
selection factors that makes the siblings/twins similar (127). For twins, the comparison also 
accounts for all confounds associated with age, shared prenatal factors that make the twins 
similar and factors correlated with sex in MZ twins and DZ same-sexed twins. However, 
sibling and twin comparisons also have limitations; they do not rule out factors that make the 
siblings/twins dissimilar (non-shared factors). 
5.4.2 Selection of participants 
The study subjects in this thesis are all members of cohort samples from some theoretical 
source population. Subjects that meet a set of inclusion criteria (e.g. inclusion in a register, 
birth year, participation in data collection, etc.) are selected and followed for a fixed period of 
time (Study I and II). Subject can also be followed prospectively and individuals may be 
censored due to migration or death, as is the case in Study IV. 
Other than fulfilling features that define the source population in Study I (such as being a twin 
at 9 or 12 years of age living in Sweden with Swedish-speaking parents), the twins of CATSS 
were characterized by their parents willingness to participate in the study. Participation can be 
associated with socio-economic status (157) or family history of disease (158). Any greater 
influence from potential unmeasured common causes of participation (such as socio-
economic status or family history of asthma) on the association between birth weight and 
asthma (as illustrated in figure 11, page 15) is, however, considered unlikely especially with 
respect to within-twin pair birth weight. In addition, a response rate of almost 80% should 
diminish concerns about strong volunteer selection. 
In Study II, a second level of criteria for participation from the CATSS study was included, 
namely agreeing to a clinical examination. The overall response rate was 52% in the study, 
and somewhat higher in MZ twins compared to DZ twins (57% and 47% respectively). The 
group of twins where no one in the pair had a history of asthma or wheeze, independent of 
zygosity, had the highest participation rate. The clinical examinations were performed at 
eight pediatric clinics or test centers around Sweden, and the twins and families were 
reimbursed for travel and living expenses. Thus, individuals should not have been self-
excluded due to economic reasons, although other reasons for being unable to travel may 
have affected the participation for some families. Generally, representativeness is most likely 
only a concern if one believes that the association between fetal growth and lung function 
would be due to a different etiology in those who did not participate (159). 
In Study III, random samples of individuals were selected from the source population, thus 
reducing risk of self-selection, or selection due to prescribing patterns or socio-economic 
status. However, the head of each health care unit decided whether or not to send the medical 
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records for each patient. Nevertheless, we did not find any regional differences in the 
proportion of received medical records.  
In Study IV, the study population was restricted to children born to women living in Sweden 
during their whole pregnancy. Follow-up was censored at the study outcome of asthma, 
emigration, death or end of study period, whichever occurred first. Less than 1% of the 
children emigrated and 0.3% were lost to follow-up due to death. Thus, selection due to loss-
of-follow up is considered unlikely.  
5.4.3 Measurement error 
Asthma 
In Study I, the main outcome of asthma was defined based on an affirmative answer to “Has 
your child ever had asthma?”, which is a question from the ISAAC questionnaire (26). 
Mistaking other respiratory noises as asthma symptoms may lead to over-reporting (160), 
therefore misclassification of the outcome has to be considered. In a Swedish validation 
study of the ISAAC questionnaire, parental reported prevalence was significantly higher 
compared to information based on medical records (161). Nonetheless, we obtained similar 
results using secondary outcomes of at least one asthma attack during the past 12 months or 
a doctor’s diagnosis of asthma. In addition, the potential misclassification is most likely 
non-differential with regard to the exposure.  
In Study II, in analyses of asthma as a mediator or effect modifier, current asthma was 
defined as affirmative answers to both “Does your child have asthma?” and “Has your child 
had wheezing or whistling in the chest in the last 12 months?”. For this study we also had 
information on prescribed asthma medications in the SPDR and asthma diagnoses in the 
NPR, and used the validated asthma outcome measurement from Study III to confirm 90% of 
the parentally reported asthma cases.  
In Study IV asthma was defined on the basis of Study III. As the majority of our study 
population in Study IV was of pre-school age, there was a concern that only using asthma 
medication as a proxy as the outcome, would not be satisfactory, since 25% were classified as 
having other asthma-like diagnosis. Thus, we chose to define asthma as a diagnosis in the 
NPR and asthma medication in the SPDR according to the criteria in Study III. This stricter 
definition reduces the number of cases, as the majority of children receive an asthma 
diagnosis in the primary health care clinic, which does not report to the NPR. This means that 
some of those that are classified as discordant sibling pairs in the analyses may actually be 
concordant. On the other hand, sensitivity analyses using asthma medication and diagnosis as 
separate outcomes, gave similar results and did not affect the study conclusion.  
Lung function 
In Study II, lung function was measured with dynamic spirometry according to ATS/ERS 
guidelines by trained personnel blinded for the exposure and asthma status (21). Accordingly, 
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any imprecision in the lung function measurement due to low cooperation or weak technique 
is most likely non-differential with respect to the exposure variables. It could be discussed 
whether post bronchodilator change in FEV1 reflects a true effect of the bronchodilator or if it 
reflects an improvement in technique. We found no indication that the technique improved 
significantly from pre to post bronchodilator assessment, as approximately 87% of the twins 
had reproducible measures of FEV1 before bronchodilator, while 88% had reproducible 
measures afterwards.  
Birth characteristics 
The foundation of the association between fetal growth and asthma or lung function mainly 
relies on proxies of growth at birth. As discussed in the introduction, both proxy measures of 
fetal growth and fetal growth per se are determined by many factors. Unrelated individuals 
may differ in these measures due to differences in gestational age, genetics, environment, and 
maternal constitution. When comparisons are made within-twin pairs all factors shared by the 
twins are held constant, thus growth discordance in twins is mainly a result of unequal share 
of supply and difference in genetic factors in DZ twins.  
The potential influence from cross-misclassification needs to be considered in within-twin 
pair comparison of exposures, such as birth weight. Assigning a twin characteristic of its co-
twin will distort any true association and lead spurious associations. In Study I and II, efforts 
were made to minimize cross-misclassification, by comparing information on birth weight 
and birth order from the MBR with parental-reported information.  
Antibiotics 
In Study IV, antibiotic exposure was defined as having filled a prescription of antibiotics, 
which is not equal to adherence to treatment (162), and as a result we may have 
overestimated the actual number of exposed. Furthermore, we did not have any information 
on the actual indication for the antibiotics, but instead divided them into three groups based 
on treatment guidelines and expertise knowledge. Our main purpose was to keep the group of 
urinary tract/skin antibiotics “as clean as possible” and making sure that antibiotics which 
may be prescribed for both urinary tract/skin infections and for airway infections (e.g. 
cephalosporins), were excluded from the urinary tract/skin antibiotic group. By doing this, we 
aimed to avoid misclassification of this group of antibiotics to further assess confounding 
from respiratory infections.  
5.5 EXTERNAL VALIDITY 
Generalizability (i.e. external validity) of twin studies to the general population is regularly 
questioned. A potential threat to representativeness could be if twins were to be different 
from singletons with respect to underlying biological mechanisms for the phenotype under 
study. In regards to the fetal programming theory, it has been suggested that the growth 
restraint that twins experience compared to singletons, would put twins at a different risk of 
subsequent disease. Studies investigating the risk of asthma in twins compared to singletons, 
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have reported inconsistent results, with some reporting a decreased risk of asthma in twins 
compared to singletons (163, 164) whereas others report no significant differences (165, 166).
 
Preliminary results from our research group report an increased risk of childhood asthma in 
pre-school twins compared to singletons, however, this increased risk was mediated by 
gestational age and birth weight. Adjustment for these factors leads to a significantly 
decreased risk of childhood asthma in twins. Thus, the general growth constraint of twinning 
(because of shared space and supply line) may not influence subsequent asthma, whereas 
factors that makes twins experience different growth from their co-twin could. Several of 
these factors would be fetal growth determinants common also for non-twins (167).  
Generalizability to non-sibling populations from studies investigating antibiotics and asthma 
using sibling control design can be discussed. For instance, it has been reported that older 
siblings might be protective to younger siblings developing asthma (168), therefore birth 
order can be suspected to influence our results. We found a significant interaction between 
birth order and exposure for any and airway antibiotics with a slightly higher hazard ratio of 
asthma in first-born children. Yet, the hazard ratios for first-borns, non-first-borns, and the 
whole cohort independent of birth order, were very similar. Thus, it is not likely that the 
difference in effect based on birth order has any clinical implications. In addition, there was 
no significant interaction between birth order and urinary tract/skin antibiotics. It is therefore 
unlikely that the lack of an association in the sibling analyses for urinary tract/skin antibiotics 
is due to families with one child. Instead, we believe that our result imply that the association 
between antibiotics in childhood and asthma is confounded by familial factors, by indication 
or reverse causation because of respiratory infections. 
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6 CONCLUSIONS AND IMPLICATIONS 
Decreasing birth weight was associated with asthma and decreased FEV1 in childhood, 
respectively, in full cohort analyses and in within-twin pair analyses. This indicates that fetal 
growth affects future development of asthma and lung function, independent of shared 
environmental factors and gestational age. Similar findings were found in MZ and DZ twins 
and in preterm and term infants, implying that the associations also were independent of 
shared genetic factors and that prematurity cannot explain the association between fetal 
growth and asthma and lung function (Study I and II).  
Analyses of differential effects in individuals with and without asthma for the association 
between fetal growth and lung function showed similar results for non-asthmatics but not for 
asthmatics, proposing that other factors may be of importance in individuals with asthma 
(Study II). 
A high PPV was found for asthma medication as a proxy for asthma in school-age children, 
while a somewhat lower PPV was found for pre-school children. A large proportion of both 
pre-school and school-age children with reported asthma diagnoses in the NPR fulfilled pre-
defined criteria of asthma. Thus, asthma medication may function as a valid measure of 
asthma in itself in children of school-age and older, while asthma medication in combination 
with an asthma diagnosis may be used in future studies of pre-school children in order to 
avoid misclassification from obstructive bronchitis (Study III). 
Exposure to antibiotics during fetal life was associated with an increased risk of asthma in 
full cohort analyses, but not in analyses using siblings without asthma as controls to siblings 
with asthma. This indicates that shared genetic and environmental factors confound the 
association between fetal antibiotic exposure and asthma (Study IV).  
Exposure to antibiotics in early childhood was associated with an increased risk of asthma in 
full cohort analyses. In analyses using sibling controls, the association disappeared for urinary 
tract/skin antibiotics and decreased markedly for airway antibiotics, implying that shared 
genetic and environmental factors confound the association between early life antibiotic 
exposure and asthma. The remaining effect of airway antibiotics may be caused by 
confounding by indication or reverse causation, which is not accounted for in the sibling 
analyses (Study IV). 
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7 FUTURE PERSPECTIVE 
Pregnancy is evidently an immensely important time for future health, but whether insults, 
such as impaired fetal growth, that disturb normal lung development can manifest as asthma 
is most likely only one part of this emerging story. Though we believe within-twin pair 
comparisons can provide valuable indications about the role of fetal growth on subsequent 
health, the design is associated with challenges. Future studies in regards to the role of fetal 
environment including the nature of twins’ shared environment in utero and the reasons for 
fetal growth discordance in twins may increase our understanding whether results from twin 
studies are generalizable to the general population.  
As MZ twins share all their genes and intrauterine environment, dissimilarities between the 
individuals in a MZ twin pair could be an effect of environmental factors or genetic variation 
that arises in utero after the splitting of the fertilized egg or after birth. As we and others have 
reported that fetal growth, independently of shared genetic and environmental factors, affects 
asthma (57, 169, 170) and measures of lung function, it can be speculated that genetic 
variants such as epigenetic changes, may be involved in the underlying causal pathway. In 
addition, longitudinal studies have suggested that lung function impairment at birth predicts 
later respiratory morbidity such as asthma (171, 172). Hence it is possible that individuals 
with lung function deficits at birth due to e.g. fetal growth restriction may be differently 
susceptible for postnatal exposures and further adverse effects of lung function and 
development of asthma, compared to infants with appropriate fetal growth. Thus, an 
improved understanding on to what level environmentally induced epigenetic changes could 
affect future health, or be inherited, is warranted. 
While our results indicate that antibiotics do not seem to cause childhood asthma, this does 
not justify increased use of antibiotics. On the contrary, bearing in mind the threat of 
antibiotic resistance, the need of antibiotics should be re-considered one more time before 
prescribing it to a child with a respiratory infection. Yet, whether our findings of a non-
causal association between antibiotics in fetal and early life and childhood asthma are the 
truth or not, is likely a debate that will continue. Whereas a randomized controlled trial seems 
unfeasible in regards to ethics, choice of comparator treatment, and low contamination 
between treatment arms, longitudinal studies with the possibility to take familial confounding 
into account have been one way to help us further understand the association between 
antibiotics and asthma. Nevertheless, confirmation of our results in other populations is of 
interest. In order to perform these types of studies a large population with known family 
constellations is needed.  
Sweden and the other Nordic countries are commonly described as gold mines for researchers 
with regards to our population-based registers as they can be used to study risk and protective 
factors for outcomes in individuals and families followed throughout life. Together, the 
Nordic countries’ registers cover over 25 million inhabitants (29) and the similarities 
between the countries’ health- and welfare system and our personal identification numbers, 
create a good platform for collaborations. Nonetheless, easily accessible collaborations are 
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hindered by practical, legal, and ethical questions that need to be solved. While validation 
studies are time-consuming and may not be regarded as ‘exciting research’, the data should 
be validated in each country and to the situation for which they are supposed to be used, since 
there may still be differences between the countries.  
So far, none of the Nordic countries have access to a population-based register with 
information from the primary health care clinics. Thus, other sources have to be used to 
identify individuals with asthma in register-based studies, and asthma medication and 
diagnosis from the drug and patient registers seem to be well-suited for this purpose (55, 173-
175). However, we have limited possibilities to investigate different phenotypes of asthma in 
the Swedish registers, which could be of importance as it has been reported that antibiotic 
exposure in childhood is associated with an increased risk of atopic asthma, but not with non-
atopic asthma (115). Moreover, a more well-structured reporting on indications of treatment 
in the SPDR would facilitate studies on potential consequences of treatments, avoid 
misclassification of exposures, and take confounding by indication further into account. In 
addition, a population-based register on drug treatments within hospitals would lead to a 
better coverage of medication use in the population. It would also make it possible to 
investigate the individual risk of in-patient treatments.   
While this thesis provides some clues about the role of fetal growth and antibiotics and the 
risk of childhood asthma and lung function impairment, the degree to which disease risk is 
established during fetal and postnatal life, the essential mechanisms, and susceptible 
developmental windows are yet to be determined. Efforts should be made to follow 
individuals from the time before pregnancy to adulthood with valid data in family designs. 
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8 ERRATA 
No thesis is perfect and that includes this one, and even before having it printed, I can report 
on two errors: 
 Paper I 
There is an error in Table 1 for the variable maternal BMI, where the number and 
percentage of individuals with asthma for each category should be BMI <18.5: 15 
(6.9%); 18.5-24.9: 774 (13.2%); 25.0-29.9: 303 (14.2%); ≥30.0: 126 (5.9%); Missing: 
283 (14.2%) 
 Paper IV 
A proof change was taken incorrectly. In the second paragraph under the statistical 
analysis section of the methods, the second sentence should have read: ”For the 
controls we used all full siblings (excluding 9896 children for whom the father’s 
identity was unknown) who did not have the outcome of interest yet and who were 
still in the study at the age at which the index child developed asthma.” The word 
”age” is missing in the published article. 
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